New research from the University of Pittsburgh reveals that sucralose, a common artificial sweetener, disrupts the efficacy of cancer immunotherapies by altering the gut microbiome. The team observed that intake of sucralose correlated with poorer responses to immune checkpoint inhibitors and decreased progression-free survival in patients with advanced skin or lung cancer. This finding, validated in mouse models, emphasizes the complex role diet and microbiome interactions can have on cancer treatment outcomes.